3.4.19.3	adrenal gland	orchidectomy increases activity of pyrrolidone carboxypeptidase type I, testosterone replacement returns it to control levels	668870	
3.4.19.3	adult	-	682806	
3.4.19.3	bloodstream form	-	667525	
3.4.19.3	brain	-	667884, 682252, 95278, 95279, 95281, 95282, 95296, 95299, 95300, 95310, 95312, 95314, 95315	
3.4.19.3	brain	cerebral cortex	95300	
3.4.19.3	brain	high levels in adenohypophysis	95309	
3.4.19.3	brain	highest activity in the synaptosomal and myelinic fractions	666460	
3.4.19.3	brain	in the cortex, activity of soluble PGP I and particulate PGP I decreases 5fold and 4fold, respectively, from the embryo to the adult	682806	
3.4.19.3	brain	pyroglutamate aminopeptidase II is predominantly localized in neuronal cells	95311	
3.4.19.3	brain	spinal cord	95314	
3.4.19.3	brain	synaptosomal fraction	653412	
3.4.19.3	colon	mucosa	653759	
3.4.19.3	embryo	-	682806	
3.4.19.3	heart	high levels of of soluble PGP I activity during the initial moments of development, in the fourth postnatal day activity starts to decrease until adulthood. Activity of the particulate form shows lowest values, during the first 20 days of life a significant decrease takes place, from this moment activity remains constant. No significant changes in activity of the particulate form	682806	
3.4.19.3	hippocampus	-	682252	
3.4.19.3	hypophysis	-	95300	
3.4.19.3	hypothalamus	-	668872, 682252, 95306	
3.4.19.3	hypothalamus	orchidectomy increases activity of pyrrolidone carboxypeptidase type I, high dose of testosterone returns activity to control levels	668870	
3.4.19.3	kidney	-	95300	
3.4.19.3	kidney	highest levels of soluble PGP I in all developmental stages, significant increase until 4 postnatal days, afterwards activity decreases slowly until 15 postnatal days, but subsequently continues to increase until 30 postnatal days. Activity of the particulate form increases until parturition day, until adulthood it remains constant with a small increase after 30 postnatal days	682806	
3.4.19.3	liver	-	731717, 95277, 95283, 95300, 95313	
3.4.19.3	liver	activity of soluble PGP I does not change significantly until 20 postnatal days, significant increase between 20-30 postnatal days. Significant decrease in the activity of the particulate form from embryonic day 22 to the fourth postnatal day, until 90 postnatal days activity remains constant	682806	
3.4.19.3	lung	high activity of soluble PGP I during the first days of development, between 20-30 postnatal days activity decreases significantly	682806	
3.4.19.3	macrophage	-	680172	
3.4.19.3	additional information	activity dysregulation at different local and systemic levels may participate in the initiation, promotion and progression of breast cancer induced in rat by N-methyl nitrosourea through the increase of gonadotropin-releasing hormone	668872	
3.4.19.3	mucosa	from colon	653759	
3.4.19.3	ovary	-	668872	
3.4.19.3	pituitary gland	anterior and posterior pituitary	668872	
3.4.19.3	pituitary gland	no change in pyrrolidone carboxypeptidase type I after orchidectomy, activity increases after administration of testosterone	668870	
3.4.19.3	promastigote	-	681817	
3.4.19.3	renal cortex	-	680172	
3.4.19.3	renal proximal tubule	-	667884	
3.4.19.3	retina	-	95306, 95309, 95310	
3.4.19.3	semen	-	708574	
3.4.19.3	semen	highest level in particulate sperm fraction. Increased activity in necrozoospermia	670862	
3.4.19.3	serum	-	95289, 95300, 95302	
3.4.19.3	skeletal muscle	-	95300	
3.4.19.3	skeletal muscle	quadriceps muscle	95301	
3.4.19.3	small intestine	pyroglutamyl-peptidase I is not involved in the aetilohy and pathology of coeliac disease	668475	
3.4.19.3	submandibular gland	-	95298	
3.4.19.3	thyroid gland	-	668872	
3.4.19.3	trypanosomoid form	-	667525	
3.4.19.3	trypomastigote	-	667525